 Sridharan Raghavan
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 23 | 2023 | 2087 | 3.950 |
Why?
| | Cardiovascular Diseases | 8 | 2022 | 1726 | 1.850 |
Why?
| | Blood Glucose | 15 | 2022 | 1827 | 1.430 |
Why?
| | Veterans | 6 | 2023 | 1248 | 1.320 |
Why?
| | Diabetes Mellitus | 6 | 2023 | 898 | 1.220 |
Why?
| | Machine Learning | 4 | 2022 | 315 | 0.890 |
Why?
| | Myocardial Infarction | 3 | 2022 | 932 | 0.870 |
Why?
| | Hypertension | 2 | 2022 | 1052 | 0.840 |
Why?
| | Dementia, Vascular | 1 | 2022 | 16 | 0.820 |
Why?
| | Coronary Artery Disease | 4 | 2022 | 611 | 0.750 |
Why?
| | Risk Factors | 18 | 2023 | 8614 | 0.730 |
Why?
| | Alzheimer Disease | 2 | 2023 | 442 | 0.720 |
Why?
| | Life Style | 2 | 2021 | 428 | 0.720 |
Why?
| | Early Medical Intervention | 1 | 2019 | 52 | 0.640 |
Why?
| | Genetic Counseling | 1 | 2019 | 65 | 0.630 |
Why?
| | Metformin | 1 | 2022 | 274 | 0.620 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 373 | 0.610 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 325 | 0.610 |
Why?
| | Models, Statistical | 2 | 2021 | 595 | 0.600 |
Why?
| | Weight Loss | 2 | 2021 | 642 | 0.600 |
Why?
| | Hypoglycemic Agents | 4 | 2022 | 1011 | 0.580 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 180 | 0.580 |
Why?
| | Secondary Prevention | 1 | 2019 | 221 | 0.570 |
Why?
| | Behavior Therapy | 1 | 2019 | 225 | 0.560 |
Why?
| | Genetic Predisposition to Disease | 5 | 2022 | 2090 | 0.550 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2019 | 286 | 0.550 |
Why?
| | Genome-Wide Association Study | 8 | 2023 | 1176 | 0.540 |
Why?
| | Research Design | 2 | 2021 | 919 | 0.520 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 428 | 0.520 |
Why?
| | Population Surveillance | 1 | 2019 | 385 | 0.520 |
Why?
| | Humans | 41 | 2023 | 114050 | 0.450 |
Why?
| | Risk Assessment | 3 | 2020 | 2958 | 0.430 |
Why?
| | Social Support | 1 | 2016 | 528 | 0.400 |
Why?
| | Mycobacterium tuberculosis | 4 | 2008 | 269 | 0.400 |
Why?
| | Polymorphism, Single Nucleotide | 8 | 2023 | 1880 | 0.400 |
Why?
| | Insulin Resistance | 3 | 2021 | 1072 | 0.400 |
Why?
| | Fasting | 3 | 2020 | 242 | 0.380 |
Why?
| | Metabolic Syndrome | 1 | 2015 | 320 | 0.380 |
Why?
| | Retrospective Studies | 10 | 2023 | 12521 | 0.370 |
Why?
| | Virulence Factors | 2 | 2008 | 139 | 0.350 |
Why?
| | Aged | 12 | 2023 | 18971 | 0.340 |
Why?
| | Incidence | 5 | 2020 | 2314 | 0.320 |
Why?
| | Adult | 12 | 2022 | 30377 | 0.310 |
Why?
| | Middle Aged | 14 | 2023 | 26607 | 0.310 |
Why?
| | Bacterial Proteins | 3 | 2008 | 735 | 0.300 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4392 | 0.280 |
Why?
| | Obesity | 3 | 2022 | 2505 | 0.260 |
Why?
| | United States | 7 | 2023 | 12137 | 0.240 |
Why?
| | Male | 18 | 2023 | 55400 | 0.240 |
Why?
| | Survival Rate | 2 | 2019 | 1638 | 0.240 |
Why?
| | Female | 18 | 2023 | 59328 | 0.230 |
Why?
| | Comorbidity | 2 | 2018 | 1447 | 0.210 |
Why?
| | Biguanides | 1 | 2022 | 12 | 0.200 |
Why?
| | Selection Bias | 1 | 2022 | 33 | 0.200 |
Why?
| | Transcription Factors | 2 | 2016 | 1526 | 0.200 |
Why?
| | Calibration | 1 | 2022 | 125 | 0.200 |
Why?
| | Causality | 1 | 2022 | 104 | 0.200 |
Why?
| | Veterans Health | 2 | 2020 | 166 | 0.190 |
Why?
| | Body Height | 1 | 2022 | 180 | 0.190 |
Why?
| | Chromosome Mapping | 1 | 2022 | 486 | 0.190 |
Why?
| | Entropy | 1 | 2021 | 35 | 0.190 |
Why?
| | Coronary Disease | 1 | 2023 | 348 | 0.180 |
Why?
| | Insurance Carriers | 1 | 2021 | 9 | 0.180 |
Why?
| | Cause of Death | 2 | 2022 | 362 | 0.180 |
Why?
| | Colonic Neoplasms | 1 | 2022 | 212 | 0.180 |
Why?
| | Macrophages | 5 | 2008 | 1259 | 0.180 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2384 | 0.180 |
Why?
| | Probability | 1 | 2021 | 286 | 0.170 |
Why?
| | Diabetic Retinopathy | 1 | 2022 | 149 | 0.170 |
Why?
| | Precision Medicine | 1 | 2023 | 335 | 0.170 |
Why?
| | Nutrition Surveys | 1 | 2021 | 225 | 0.170 |
Why?
| | Exercise | 2 | 2021 | 1642 | 0.160 |
Why?
| | Coronary Artery Bypass | 1 | 2021 | 196 | 0.160 |
Why?
| | Diabetic Nephropathies | 1 | 2022 | 234 | 0.160 |
Why?
| | Guidelines as Topic | 1 | 2021 | 241 | 0.160 |
Why?
| | Cigarette Smoking | 1 | 2020 | 74 | 0.160 |
Why?
| | Insurance, Health | 1 | 2021 | 243 | 0.160 |
Why?
| | Mendelian Randomization Analysis | 3 | 2023 | 43 | 0.150 |
Why?
| | Patient Readmission | 1 | 2023 | 607 | 0.150 |
Why?
| | Body Mass Index | 3 | 2022 | 1957 | 0.150 |
Why?
| | Diabetes Complications | 1 | 2019 | 208 | 0.150 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 926 | 0.140 |
Why?
| | Bariatric Surgery | 1 | 2020 | 160 | 0.140 |
Why?
| | Virulence | 3 | 2008 | 228 | 0.140 |
Why?
| | Blood Pressure | 2 | 2022 | 1531 | 0.140 |
Why?
| | Obesity, Morbid | 1 | 2020 | 197 | 0.140 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 153 | 0.140 |
Why?
| | Risk | 2 | 2020 | 810 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1204 | 0.130 |
Why?
| | Mortality | 1 | 2018 | 283 | 0.130 |
Why?
| | Refugees | 1 | 2016 | 54 | 0.130 |
Why?
| | Atherosclerosis | 1 | 2019 | 342 | 0.130 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2021 | 445 | 0.130 |
Why?
| | Physicians | 1 | 2023 | 765 | 0.120 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 287 | 0.120 |
Why?
| | Spouses | 1 | 2016 | 85 | 0.120 |
Why?
| | Genotype | 1 | 2020 | 1757 | 0.120 |
Why?
| | Family Health | 1 | 2016 | 193 | 0.120 |
Why?
| | Mutation Rate | 1 | 2015 | 24 | 0.120 |
Why?
| | Gene Expression Regulation, Bacterial | 2 | 2008 | 285 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 742 | 0.120 |
Why?
| | Emigrants and Immigrants | 1 | 2016 | 107 | 0.120 |
Why?
| | Prognosis | 2 | 2019 | 3315 | 0.120 |
Why?
| | Medication Adherence | 1 | 2019 | 531 | 0.110 |
Why?
| | Cardiac Catheterization | 1 | 2018 | 545 | 0.110 |
Why?
| | Exome | 1 | 2015 | 200 | 0.110 |
Why?
| | Insulin | 3 | 2021 | 2080 | 0.110 |
Why?
| | Tuberculosis | 2 | 2008 | 241 | 0.110 |
Why?
| | Young Adult | 4 | 2021 | 10446 | 0.100 |
Why?
| | Age Factors | 1 | 2019 | 2886 | 0.100 |
Why?
| | Telemedicine | 1 | 2020 | 662 | 0.100 |
Why?
| | Stroke | 1 | 2019 | 1019 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2537 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2021 | 9049 | 0.090 |
Why?
| | Sample Size | 2 | 2022 | 109 | 0.090 |
Why?
| | Genetic Variation | 1 | 2015 | 868 | 0.080 |
Why?
| | Time Factors | 1 | 2019 | 6077 | 0.080 |
Why?
| | Mycobacterium marinum | 1 | 2008 | 2 | 0.080 |
Why?
| | Gene Frequency | 2 | 2022 | 476 | 0.080 |
Why?
| | Operon | 1 | 2008 | 59 | 0.080 |
Why?
| | Lysosomes | 1 | 2008 | 123 | 0.070 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2008 | 30 | 0.070 |
Why?
| | Cohort Studies | 3 | 2023 | 4883 | 0.070 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2020 | 73 | 0.070 |
Why?
| | Toll-Like Receptors | 1 | 2008 | 167 | 0.070 |
Why?
| | Listeria monocytogenes | 1 | 2008 | 111 | 0.070 |
Why?
| | Mice, Inbred C57BL | 4 | 2008 | 4681 | 0.070 |
Why?
| | Transcriptional Activation | 1 | 2008 | 337 | 0.070 |
Why?
| | Phagocytosis | 1 | 2008 | 349 | 0.070 |
Why?
| | Genetic Loci | 2 | 2020 | 262 | 0.070 |
Why?
| | Immunity, Cellular | 1 | 2008 | 247 | 0.060 |
Why?
| | Glucose | 2 | 2021 | 899 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2008 | 1310 | 0.060 |
Why?
| | Phenotype | 2 | 2022 | 2784 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1690 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1131 | 0.060 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2008 | 328 | 0.050 |
Why?
| | Clonal Evolution | 1 | 2023 | 25 | 0.050 |
Why?
| | Hematopoiesis | 1 | 2023 | 170 | 0.050 |
Why?
| | Linkage Disequilibrium | 1 | 2022 | 245 | 0.050 |
Why?
| | Skilled Nursing Facilities | 1 | 2023 | 121 | 0.050 |
Why?
| | Europe | 1 | 2022 | 332 | 0.050 |
Why?
| | United Kingdom | 1 | 2022 | 226 | 0.050 |
Why?
| | Mice | 5 | 2008 | 14845 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2022 | 94 | 0.050 |
Why?
| | Albuminuria | 1 | 2022 | 164 | 0.050 |
Why?
| | Consensus | 1 | 2023 | 532 | 0.050 |
Why?
| | Haplotypes | 1 | 2022 | 448 | 0.050 |
Why?
| | Genome, Human | 1 | 2022 | 347 | 0.040 |
Why?
| | Fee-for-Service Plans | 1 | 2021 | 83 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 307 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 184 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 662 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2322 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2022 | 605 | 0.040 |
Why?
| | Decision Trees | 1 | 2018 | 82 | 0.040 |
Why?
| | Medicare | 1 | 2023 | 661 | 0.040 |
Why?
| | Genomics | 1 | 2022 | 631 | 0.040 |
Why?
| | Exercise Test | 1 | 2021 | 547 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 441 | 0.040 |
Why?
| | Homeostasis | 1 | 2021 | 570 | 0.040 |
Why?
| | Patient Discharge | 1 | 2023 | 770 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2020 | 735 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2020 | 561 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 951 | 0.030 |
Why?
| | Massachusetts | 1 | 2016 | 134 | 0.030 |
Why?
| | Animals | 5 | 2008 | 31567 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2016 | 81 | 0.030 |
Why?
| | Introns | 1 | 2016 | 227 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2016 | 151 | 0.030 |
Why?
| | Glucose-6-Phosphatase | 1 | 2015 | 31 | 0.030 |
Why?
| | Cells, Cultured | 3 | 2008 | 3861 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 1762 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2016 | 304 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1360 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1078 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 1829 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2017 | 1656 | 0.030 |
Why?
| | Mutation | 1 | 2023 | 3338 | 0.030 |
Why?
| | Adolescent | 2 | 2021 | 17802 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2015 | 339 | 0.030 |
Why?
| | Mass Screening | 1 | 2019 | 979 | 0.030 |
Why?
| | Prospective Studies | 1 | 2023 | 6195 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2764 | 0.020 |
Why?
| | Islets of Langerhans | 1 | 2016 | 728 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2016 | 799 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 6307 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 5499 | 0.020 |
Why?
| | Registries | 1 | 2016 | 1764 | 0.020 |
Why?
| | CARD Signaling Adaptor Proteins | 1 | 2008 | 17 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3397 | 0.020 |
Why?
| | Caspase 1 | 1 | 2008 | 140 | 0.020 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2008 | 44 | 0.020 |
Why?
| | Cytoskeletal Proteins | 1 | 2008 | 145 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2008 | 170 | 0.020 |
Why?
| | Hemolysis | 1 | 2008 | 143 | 0.020 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2008 | 90 | 0.020 |
Why?
| | Macrophage Activation | 1 | 2008 | 163 | 0.020 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2008 | 144 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 171 | 0.020 |
Why?
| | Interleukin-18 | 1 | 2008 | 217 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2008 | 368 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 2005 | 62 | 0.020 |
Why?
| | Two-Hybrid System Techniques | 1 | 2005 | 52 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2005 | 103 | 0.020 |
Why?
| | Genes, Bacterial | 1 | 2005 | 157 | 0.020 |
Why?
| | Antigens, Bacterial | 1 | 2005 | 111 | 0.010 |
Why?
| | Multigene Family | 1 | 2005 | 190 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 694 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2003 | 218 | 0.010 |
Why?
| | Plasmids | 1 | 2003 | 343 | 0.010 |
Why?
| | Calcium | 1 | 2008 | 1089 | 0.010 |
Why?
| | Child | 1 | 2021 | 18404 | 0.010 |
Why?
| | Protein Transport | 1 | 2003 | 391 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2008 | 2563 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2005 | 1981 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 281 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2008 | 1518 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2783 | 0.010 |
Why?
| | Inflammation | 1 | 2008 | 2464 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1611 | 0.010 |
Why?
| | Signal Transduction | 1 | 2008 | 4501 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2003 | 3498 | 0.010 |
Why?
|
|
Raghavan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|